A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901Toshiyuki Harada, Masaharu Nishimura, Kenichiro Ito et al.|The Oncologist|2013Cited by 14